These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34231434)

  • 1. How urgent is the need for new antifungals?
    Stewart AG; Paterson DL
    Expert Opin Pharmacother; 2021 Oct; 22(14):1857-1870. PubMed ID: 34231434
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging Diagnostics and Therapeutics for Invasive Fungal Infections.
    Friedman DZP; Schwartz IS
    Infect Dis Clin North Am; 2023 Sep; 37(3):593-616. PubMed ID: 37532392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future Fungal Fighters in Dermatology: Novel Antifungal Drug Pipeline.
    Khalfe Y; Rosen T
    J Drugs Dermatol; 2022 May; 21(5):496-501. PubMed ID: 35533026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.
    Hoenigl M; Sprute R; Arastehfar A; Perfect JR; Lass-Flörl C; Bellmann R; Prattes J; Thompson GR; Wiederhold NP; Al Obaidi MM; Willinger B; Arendrup MC; Koehler P; Oliverio M; Egger M; Schwartz IS; Cornely OA; Pappas PG; Krause R
    Expert Opin Investig Drugs; 2022 Aug; 31(8):795-812. PubMed ID: 35657026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective.
    Hsu AJ; Hanisch BR; Fisher BT; Huppler AR
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S68-S79. PubMed ID: 38417087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective.
    Lamoth F; Lewis RE; Kontoyiannis DP
    Clin Infect Dis; 2022 Aug; 75(3):534-544. PubMed ID: 34986246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antifungal pipeline for invasive fungal diseases: what does the future hold?
    Neoh CF; Jeong W; Kong DC; Slavin MA
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):577-594. PubMed ID: 37057677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for critically important WHO fungal priority pathogens.
    Kriegl L; Egger M; Boyer J; Hoenigl M; Krause R
    Clin Microbiol Infect; 2024 Mar; ():. PubMed ID: 38461942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antifungal agents in clinical trials.
    Jacobs SE; Zagaliotis P; Walsh TJ
    F1000Res; 2021; 10():507. PubMed ID: 35136573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative therapies for invasive fungal infections in preclinical and clinical development.
    Yu Y; Albrecht K; Groll J; Beilhack A
    Expert Opin Investig Drugs; 2020 Sep; 29(9):961-971. PubMed ID: 32662681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
    Hoenigl M; Sprute R; Egger M; Arastehfar A; Cornely OA; Krause R; Lass-Flörl C; Prattes J; Spec A; Thompson GR; Wiederhold N; Jenks JD
    Drugs; 2021 Oct; 81(15):1703-1729. PubMed ID: 34626339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
    August BA; Kale-Pradhan PB
    Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Antifungal Agents: Current Status and Projected Future Developments.
    Seyedmousavi S; Rafati H; Ilkit M; Tolooe A; Hedayati MT; Verweij P
    Methods Mol Biol; 2017; 1508():107-139. PubMed ID: 27837500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.
    Wiederhold NP
    J Fungi (Basel); 2022 Aug; 8(8):. PubMed ID: 36012845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in Clinical Development for Fungal Infections.
    Gonzalez-Lara MF; Sifuentes-Osornio J; Ostrosky-Zeichner L
    Drugs; 2017 Sep; 77(14):1505-1518. PubMed ID: 28840541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antifungal arsenal: alternative drugs and future targets.
    Wiederhold NP
    Int J Antimicrob Agents; 2018 Mar; 51(3):333-339. PubMed ID: 28890395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species.
    Silva LN; de Mello TP; de Souza Ramos L; Branquinha MH; Dos Santos ALS
    Curr Top Med Chem; 2019; 19(28):2527-2553. PubMed ID: 31654512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances and future perspectives in the pharmacological treatment of
    Giacobbe DR; Magnasco L; Sepulcri C; Mikulska M; Koehler P; Cornely OA; Bassetti M
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1205-1220. PubMed ID: 34176393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinatorial strategies for combating invasive fungal infections.
    Spitzer M; Robbins N; Wright GD
    Virulence; 2017 Feb; 8(2):169-185. PubMed ID: 27268286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
    Neoh CF; Chen SC; Lanternier F; Tio SY; Halliday CL; Kidd SE; Kong DCM; Meyer W; Hoenigl M; Slavin MA
    Clin Microbiol Rev; 2024 Jun; 37(2):e0000423. PubMed ID: 38551323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.